Decision by Sponsor

An 39-week plus extensions, open-label study to estimate the reduction in HbA1c in patients with initial HbA1c >10% \

Inclusion Criteria:

• Men or women age 18 to 80 years with type 2 diabetes
• On stable treatment regimen of diet and exercise alone or in combination with a stable & optimal or near-optimal dose of metformin, sulfonylurea, TZD or combination of these drugs
• HbA1c >10.0% and ≤12.0%

Exclusion Criteria:

• Prior treatment with any GLP-1 receptor agonist
• History of hypersensitivity to exenatide or liraglutide
• FPG >300 mg/dL
• History of medullary thyroid cancer or a family or personal history of multiple endocrine neoplasia type 2
• Taking DPP-4 inhibitors, incretin mimetics, alpha glucosidase inhibitors, meglitinides or insulin within last 3 months
• history of pancreatitis